Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult

Blood

Volumn 130, Issue 11, 2017, Pages 1327-1335

  Morris, Emma C ^a,b   Fox, Thomas ^a   Chakraverty, Ronjon ^a,b   Tendeiro, Rita ^a   Snell, Katie ^c,d   Rivat, Christine ^c   Grace, Sarah ^b   Gilmour, Kimberly ^d   Workman, Sarita ^b   Buckland, Karen ^c   Butler, Katie ^c   Chee, Ronnie ^b   Salama, Alan D ^a   Ibrahim, Hazem ^b   Hara, Havinder ^c   Duret, Cecile ^c   Mavilio, Fulvio ^e   Male, Frances ^f   Bushman, Frederick D ^f   Galy, Anne ^e   Burns, Siobhan O ^a,b   Gaspar, H Bobby ^c,d   Thrasher, Adrian J ^c,d   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e GÉNÉTHON   (France)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CD4 ANTIGEN; CD8 ANTIGEN; COTRIMOXAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; LENOGRASTIM; METHYLPREDNISOLONE; PENICILLIN V; PLERIXAFOR; VORICONAZOLE; CYTOKINE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CASE REPORT; CELL LINEAGE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EPISTAXIS; GENE TRANSFER; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTOPENIA; WISKOTT ALDRICH SYNDROME; BLOOD; CELL CLONE; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); GENE THERAPY; GENETICS; IMMUNOLOGY; PRESCHOOL CHILD; T LYMPHOCYTE; VACCINATION; WISKOTT-ALDRICH SYNDROME;

ADULT; CELL PROLIFERATION; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CLONE CELLS; CYTOKINES; GENETIC THERAPY; HUMANS; LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; VACCINATION; WISKOTT-ALDRICH SYNDROME;

EID: 85029504375     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-04-777136     Document Type: Article

References (27)

1. Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol. 2010;10(3):182-192.
2. Baptista MA, Keszei M, Oliveira M, et al. Deletion of Wiskott-Aldrich syndrome protein triggers Rac2 activity and increased cross-presentation by dendritic cells. Nat Commun. 2016;7:12175.
3. Burns S, Cory GO, Vainchenker W, Thrasher AJ. Mechanisms of WASp-mediated hematologic and immunologic disease. Blood. 2004;104(12): 3454-3462.
4. Meyer-Bahlburg A, Becker-Herman S, Humblet-Baron S, et al. Wiskott-Aldrich syndrome protein deficiency in B cells results in impaired peripheral homeostasis. Blood. 2008;112(10):4158-4169.
5. Worth AJ, Thrasher AJ. Current and emerging treatment options for Wiskott-Aldrich syndrome. Expert Rev Clin Immunol. 2015;11(9):1015-1032.
6. Zhu Q, Zhang M, Blaese RM, et al. The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. Blood. 1995;86(10):3797-3804.
7. Pai SY, DeMartiis D, Forino C, et al. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant. 2006;38(10):671-679.
8. Pai SY, Notarangelo LD. Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: advances in biology and future directions for treatment. Immunol Allergy Clin North Am. 2010; 30(2):179-194.
9. Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood. 2011;118(6):1675-1684.
10. Kharya G, Nademi Z, Leahy TR, et al. Haploidentical T-cell alpha beta receptor and CD19-depleted stem cell transplant for Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2014; 134(5):1199-1201.
11. Locatelli F, Bauquet A, Palumbo G, Moretta F, Bertaina A. Negative depletion of a/b1 T cells and of CD191 B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Immunol Lett. 2013;155(1-2):21-23.
12. Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome: long-term efficacy and genotoxicity. Sci Transl Med. 2014;6(227):227ra33.
13. Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013; 341(6148):1233151.
14. Hacein-Bey Abina S, Gaspar HB, Blondeau J, et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA. 2015;313(15):1550-1563.
15. Sherman E, Nobles C, Berry CC, et al. INSPIIRED: a pipeline for quantitative analysis of sites of new DNA integration in cellular genomes. Mol Ther Methods Clin Dev. 2017;4:39-49.
16. Berry CC, Nobles C, Six E, et al. INSPIIRED: quantification and visualization tools for analyzing integration site distributions. Mol Ther Methods Clin Dev. 2016;4:17-26.
17. Berry C, Hannenhalli S, Leipzig J, Bushman FD. Selection of target sites for mobile DNA integration in the human genome. PLOS Comput Biol. 2006;2(11):e157.
18. Berry CC, Ocwieja KE, Malani N, Bushman FD. Comparing DNA integration site clusters with scan statistics. Bioinformatics. 2014;30(11):1493-1500.
19. Berry CC, Gillet NA, Melamed A, Gormley N, Bangham CR, Bushman FD. Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics. 2012;28(6): 755-762.
20. Zhu Q, Watanabe C, Liu T, et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood. 1997;90(7):2680-2689.
21. Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich syndrome protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 2004; 104(13):4010-4019.
22. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8): 2912-2919.
23. Chao A. Estimating the population size for capture-recapture data with unequal catchability. Biometrics. 1987;43(4):783-791.
24. Westerberg LS, de la Fuente MA, Wermeling F, et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood. 2008;112(10):4139-4147.
25. Starnes TW, Bennin DA, Bing X, et al. The F-BAR protein PSTPIP1 controls extracellular matrix degradation and filopodia formation in macrophages. Blood. 2014;123(17):2703-2714.
26. Ristow HJ. A major factor contributing to epidermal proliferation in inflammatory skin diseases appears to be interleukin 1 or a related protein. Proc Natl Acad Sci USA. 1987;84(7):1940-1944.
27. Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016;175(5):882-891.